Your browser doesn't support javascript.
loading
Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy.
Xie, Congying; Yang, Pengfei; Zhang, Xuebang; Xu, Lei; Wang, Xiaoju; Li, Xiadong; Zhang, Luhan; Xie, Ruifei; Yang, Ling; Jing, Zhao; Zhang, Hongfang; Ding, Lingyu; Kuang, Yu; Niu, Tianye; Wu, Shixiu.
Afiliação
  • Xie C; Cancer Centre, First Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, PR China.
  • Yang P; Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China; College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, Zhejiang, PR China.
  • Zhang X; Cancer Centre, First Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, PR China.
  • Xu L; Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.
  • Wang X; Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, PR China.
  • Li X; Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China; Department of Radiation Therapy, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, PR China.
  • Zhang L; Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.
  • Xie R; Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, PR China.
  • Yang L; Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, PR China.
  • Jing Z; Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, PR China.
  • Zhang H; Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, PR China.
  • Ding L; Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, PR China.
  • Kuang Y; Department of Medical Physics, University of Nevada, Las Vegas, Las Vegas, NV, USA.
  • Niu T; Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China. Electronic address: tyniu@zju.edu.cn.
  • Wu S; National Cancer Center/National Clinical Research Center For Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, PR China. Electronic address: wushixiu@medmail.com.cn.
EBioMedicine ; 44: 289-297, 2019 Jun.
Article em En | MEDLINE | ID: mdl-31129097
ABSTRACT

BACKGROUND:

Evaluating clinical outcome prior to concurrent chemoradiotherapy remains challenging for oesophageal squamous cell carcinoma (OSCC) as traditional prognostic markers are assessed at the completion of treatment. Herein, we investigated the potential of using sub-region radiomics as a novel tumour biomarker in predicting overall survival of OSCC patients treated by concurrent chemoradiotherapy.

METHODS:

Independent patient cohorts from two hospitals were included for training (n = 87) and validation (n = 46). Radiomics features were extracted from sub-regions clustered from patients' tumour regions using K-means method. The LASSO regression for 'Cox' method was used for feature selection. The survival prediction model was constructed based on the sub-region radiomics features using the Cox proportional hazards model. The clinical and biological significance of radiomics features were assessed by correlation analysis of clinical characteristics and copy number alterations(CNAs) in the validation dataset.

FINDINGS:

The overall survival prediction model combining with seven sub-regional radiomics features was constructed. The C-indexes of the proposed model were 0.729 (0.656-0.801, 95% CI) and 0.705 (0.628-0.782, 95%CI) in the training and validation cohorts, respectively. The 3-year survival receiver operating characteristic (ROC) curve showed an area under the ROC curve of 0.811 (0.670-0.952, 95%CI) in training and 0.805 (0.638-0.973, 95%CI) in validation. The correlation analysis showed a significant correlation between radiomics features and CNAs.

INTERPRETATION:

The proposed sub-regional radiomics model could predict the overall survival risk for patients with OSCC treated by definitive concurrent chemoradiotherapy. FUND This work was supported by the Zhejiang Provincial Foundation for Natural Sciences, National Natural Science Foundation of China.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radiometria / Neoplasias Esofágicas / Quimiorradioterapia Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radiometria / Neoplasias Esofágicas / Quimiorradioterapia Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article